Mass General Brigham researchers from the Gene Lay Institute of Immunology and Inflammation, along with researchers at Dana-Farber Cancer Institute, and the Broad Institute, have uncovered biological clues to why colorectal cancer can behave more aggressively in younger people.

Published today in Nature Medicine, the study — the largest of its kind — lays a foundation for understanding age-associated differences in colorectal cancer and exploring future treatments.

In the United States, colorectal cancer diagnosis rates among people younger than 50 rose 2.9% per year from 2013 through 2022, according to the American Cancer Society.

Its 2026 report identifies colorectal cancer as the leading cause of cancer death in this age group.

Younger patients are also more likely to be diagnosed at advanced stages, underscoring the need to better understand the biology of early-onset disease.

“The need to understand why colorectal cancer is affecting younger adults at increasing rates is urgent,” said co-senior author Ana C. Anderson, PhD, a core faculty member of the Gene Lay Institute of Immunology and Inflammation at Brigham and Women’s Hospital, Massachusetts General Hospital, and Harvard Medical School, who co-directed the project.

“And that starts with understanding the biology of the disease across the entire lifespan. By looking beyond conventional age cutoffs, we’ve uncovered biological patterns that earlier studies may have missed and created a foundation for the field to investigate them further. While we’re still at the beginning of understanding what these differences mean, our work gives researchers a new direction to pursue in tackling this urgent problem in human disease.”

The research team, led by first author Caroline Porter, PhD, of the Klarman Cell Observatory at the Broad Institute, studied specimens from surgeries at Brigham and Women’s Hospital and stored in Dana-Farber’s Gastrointestinal Biobank.

Co-senior authors include Anderson, Kimmie Ng, MD, MPH, of Dana-Farber Cancer Institute, and Ramnik J. Xavier, MD, PhD, of the Broad Institute and Mass General Brigham and the Gene Lay Institute.

They analysed 189 tumours from patients ages 29 to 90+, including 54 diagnosed before age 50, and 135 diagnosed at age 50 or older.

Using a technique called single-nucleus RNA sequencing, the researchers measured gene activity in more than 850,000 cancer cells and other cells in the tumours.

The technique, which works with frozen tissue, enabled the team to build a detailed map of tumour cells by studying archived samples with extensive clinical record data.

Rather than dividing the tumour samples into two data sets and comparing the younger and older age groups, the researchers looked for factors that changed gradually with age, accounting for tumour location, stage, sex, and prior treatment in their analyses.

This approach revealed subtle differences that likely would have been obscured by a simple two-data set comparison.

Among tumours of the most common colorectal cancer subtype, younger patients’ tumours had a significantly higher proportion of connective and supporting cells relative to cancer cells.

A higher proportion of connective and supporting cells has been linked to chemotherapy resistance in several types of solid cancer.

The team confirmed this pattern using gene-activity data from 564 other tumours and computer analysis of stained tissue images from another 712 tumours.

Younger patients also had higher activity of long non-coding RNAs, molecules that can regulate genes without making proteins.

Some appeared repeatedly across different types of cancer cells.

Many are “dark” RNAs, whose functions remain largely unknown.

The team also saw gene activity suggesting stronger signalling between cells that can help cancer cells move and invade nearby tissue in younger patients.

“Our study is an advance from previous work in that we analysed tumours from a large number of patients and used single-cell approaches to find novel features unique to tumours from young patients,” said Xavier, a co-senior author of the study, a core institute member at the Broad Institute, and Kurt Isselbacher Professor at Massachusetts General Hospital and Harvard Medical School and Vice Director of the Gene Lay Institute.

Xavier is also a gastroenterologist at Mass General Brigham.

“This work sets the stage for future mechanistic studies on how these cell programmes interact with chemicals from the diet and from gut microbes to cause early-onset colorectal cancer.”

Although the findings provide key insight into colorectal cancer in young individuals, they do not yet provide proof that these differences cause more aggressive disease.

One remaining question is whether there are differences in immune responses in these tumours across ages — the researchers methods captured relatively few immune cells.

Future studies will explore how these changes may affect cancer growth and spread, and whether they offer opportunities for prevention or treatment.

“Through Dana-Farber’s Young-Onset Colorectal Cancer Centre, we see how profoundly this disease can affect younger patients and their families, often during the busiest and most formative years of life,” said co-senior author Ng, who is the director of the Young-Onset Colorectal Cancer Centre at Dana-Farber.

“This collaborative work with Mass General Brigham researchers from the Gene Lay Institute and researchers from the Broad Institute gives us important new insight into the biology of these tumours. The findings provide a valuable roadmap for further investigating the distinct features of young-onset colorectal cancer. Our ultimate goal is to discover novel strategies for prevention, diagnosis, and treatment for our young patients.”

Source: Mass General Brigham